Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).
BACKGROUND
Diphenylcyclopropenone (DPCP) has been reported to be an effective topical immunotherapy of extensive alopecia areata (AA) with highly variable reported results.


OBJECTIVE
The purposes of this study were to assess the efficacy, side effects, and adverse prognostic factors in the treatment of alopecia areata with DPCP.


METHODS
21 patients were included in the study with chronic and extensive AA. Patients were sensitized in the beginning with 2% DPCP, and the concentrations were increased gradually beginning with 0.000001% every one to two weeks for a period of 6 months.


RESULTS
15 patients (71.4%) had a complete or partial recovery at the end of the treatment period. Most frequent side effects were erythema at the site of application, pigmentation, and lymph node enlargement. The most important adverse prognostic factors were duration of AA, history of atopy, and presence of nail changes.


CONCLUSIONS
Treatment of AA with topical DPCP is effective. Though the treatment may have some side effects, in most cases they are tolerable and respond well to treatment.
Galadari
I
I
Faculty of Medicine and Health Sciences, UAE University, Dermatology Department, Al-Ain Hospital, Al-Ain, UAE.
Rubaie
S
S
Alkaabi
J
J
Galadari
H
H
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000506:Alopecia Areata / Q000188:drug therapy*; D002648:Child; D002908:Chronic Disease; D003521:Cyclopropanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D003521:Cyclopropanes; C029402:diphenylcyclopropenone